![[ Visit Client Website ]](images/banner.jpg)
Q & A Workshop
Indicates that handouts are availableFriday, February 28, 2014
5:00 PM-6:15 PM
1802
Difficult to Manage Asthma: The Very Young, the Very Old and the Obese
Session Details
Learning Objectives:
Session Details
Friday, February 28, 2014: 5:00 PM-6:15 PM
Convention Center, Mezzanine Level, Room 14AB
1.25 CME/ 1.50 CE
Moderator:
Timothy J. Craig , DO FAAAAI
- Identify emerging diagnostic modalities for asthma that may be useful in children under age 5 years
- Develop strategies to distinguish asthma from other potential comorbid conditions in elderly asthmatics and implement age-appropriate management strategies in older asthmatics
- Summarize recent data regarding the obese asthmatic phenotype and critically assess current management strategies in this subgroup of asthmatics
1803
What are Damp Buildings and How Do They Cause Problems?
Session Details
Learning Objectives:
Session Details
Friday, February 28, 2014: 5:00 PM-6:15 PM
Convention Center, Upper Level, Room 5AB
1.25 CME/ 1.50 CE
Moderator:
Jay M. Portnoy , MD FAAAAI
- Review the multiple expert panels / reports and Position Statements concluding that there is adequate evidence for respiratory health impacts, including new onset asthma, due to damp buildings
- Describe the challenges of quantifying dampness and establishing acceptable moisture levels
- Recognize the several plausible mechanisms that underlie the adverse respiratory impacts of the damp building effect.
1804
The Science Behind Complementary and Alternative Medicine
Session Details
Learning Objectives:
Session Details
Friday, February 28, 2014: 5:00 PM-6:15 PM
Convention Center, Upper Level, Room 7AB
1.25 CME/ 1.50 CE
Moderator:
William S. Silvers , MD FAAAAI
- Explain the role of vitamin D in allergic inflammation
- Discuss the immunomodulatory effects of Chinese herbal medicine for food allergy
- Describe the role of prebiotics and probiotics in the prevention and treatment of allergy
1805
Difficult Situations in Practice Management
Session Details
Learning Objectives:
Session Details
Friday, February 28, 2014: 5:00 PM-6:15 PM
Convention Center, Mezzanine Level, Room 16AB
1.25 CME/ 1.50 CE
Moderator:
Tao T. Le , MD MHS FAAAAI
- Identify and address difficult situations regarding employment and partnership contracts
- Evaluate difficult situations in hiring and firing
- Investigate difficult situations in marketing
Saturday, March 1, 2014
4:45 PM-6:00 PM
2801
The Influence of Bisphenol A and Phthalates (Xenoestrogens) on the Development of Asthma and Allergy in Children and Adults: What’s Known and What's Real?
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Room 1AB
1.25 CME/ 1.50 CE
Moderator:
Leslie C. Grammer , MD FAAAAI
- Define the environmental sources of chemicals with estrogen properties such as bisphenol A and phthalates.
- Summarize the research demonstrating the effects of xenoestrogens on the allergic and asthmatic phenotype
- Describe the epidemiology that associates xenoestrogen exposures and the development of asthma and allergy in children and adults
2804
The Safety of Asthma Medications During Pregnancy: An Update
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Room 11AB
1.25 CME/ 1.50 CE
Moderator:
Michael Schatz , MD MS FAAAAI
- Evaluate the recent VAMPSS prospective cohort data on the safety of asthma medications in pregnancy
- Review the recent VAMPSS case-control data on the safety of asthma medications in pregnancy
- Discuss current information on the gestational safety of asthma medications to the clinical care of pregnant patients with asthma
2805
AAP: Hot Topics in Pediatric Allergy and Immunology
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Ballroom 6A
1.25 CME/ 1.50 CE
Moderator:
Todd A. Mahr , MD FAAAAI
- Discuss how these might impact the care of pediatric patients with respiratory allergic disease, food and drug allergy and immunologic disorders
- Describe the latest developments in pediatric allergy and immunology
2806
Who's on First? Primary Immunodeficiency, Autoimmune Disease or Immune Modulation
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Ballroom 6B
1.25 CME/ 1.50 CE
Moderator:
Ramsay L. Fuleihan , MD
- Discuss how autoimmunity arises in the setting of primary and secondary immunodeficiency
- Review potential infectious sequelae arising from immunomodulation
- Learn how to monitor and support immune function after immune compromise due to immunomodulator therapy
2807
Difficult Drug Allergy Cases: Case-Based Discussions
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Ballroom 6CF
1.25 CME/ 1.50 CE
Moderator:
Rebecca S. Gruchalla , MD PhD FAAAAI
- Explain management of patients with multiple drug allergies
- Describe perioperative Anaphylaxis: diagnosis, evaluation and management
- Outline the role for skin testing, test dose and desensitization
2809
Update in Occupational Allergy: A Focus on the Skin, Nose, and the Young Worker
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Room 7AB
1.25 CME/ 1.50 CE
Moderator:
Susan M. Tarlo , MBBS FAAAAI
- Review the pros and cons of skin testing for occupational allergens and recent advances in occupational skin allergy
- Identify the range of exposures causing occupational rhinitis and tools for investigation
- Discuss how to approach adolescents and young adults at risk of work-related allergic responses
2810
Molecular Pathogenesis of Aspirin Intolerance
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Room 8
1.25 CME/ 1.50 CE
Moderator:
Robert P. Schleimer , PhD FAAAAI
- Identify the molecular control mechanisms of the 5-lipoxygenase enzyme
- Identify the potential contribution from the perturbed microbiome
- Discuss the potential role of inteferon gamma in AERD
2812
Safety Challenges with Allergen Immunotherapy
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Mezzanine Level, Room 14AB
1.25 CME/ 1.50 CE
Moderator:
Matthew A. Rank , MD FAAAAI
- Discuss safety experience with Allergen Immunotherapy given to patients with a history of cancer, HIV positivity, hypertension and other underlying medical conditions
- Comment on problems that might arise theoretically and problems that have been reported with AIT in patients taking certain medications (beta-blockers, ACE inhibitors, immunosuppressive drugs, etc)
- Recognize factors in an allergy clinic associated with a higher rate of adverse events with AIT and recommend actions in their clinics that might augment safety of AIT
2813
The Epithelium in Control
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Mezzanine Level, Room 15AB
1.25 CME/ 1.50 CE
Moderator:
Angela Haczku , MD PhD FAAAAI
- Describe novel mechanisms through which epithelial TSLP drives allergic disease
- Discuss the mechanism through which epithelial derived IL-25 drives allergic disease
- Discuss how epithelial and dendritic cells contribute to IL-33 production during the allergic airway response
2814
ABAI: Help Me Help You Meet MOC Requirements
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Mezzanine Level, Room 16AB
1.25 CME/ 1.50 CE
Moderator:
Stephen I. Wasserman , MD FAAAAI
- Review the MOC requirements and how to successfully complete them
- Demonstrate tips and tricks to completing MOC requirements
- Reflect upon the personal experience of a peer who completed MOC requirements
2815
The Next Step After ICS/LABA
Session Details
Learning Objectives:
Session Details
Saturday, March 1, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Room 30ABCDE
1.25 CME/ 1.50 CE
Moderator:
Harold S. Nelson , MD FAAAAI
- List the evidence supporting the use of anticholinergic therapy in refractory asthma
- Review the evidence supporting the use of a small particle ICS over conventional ICS molecules
- Discuss recent evidence supporting the use of omalizumab treatment in difficult asthma
Monday, March 3, 2014
4:45 PM-6:00 PM
4802
Social Media: The Future is Here
Session Details
Learning Objectives:
Session Details
Monday, March 3, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Room 2
1.25 CME/ 1.50 CE
Moderator:
Melinda M. Rathkopf , MD FAAAAI
- Discuss how the utilization of social media in allergy and immunology practices can lead to improved patient education and satisfaction
- Identify a step-wise plan for the implementation and maintenance of a social media strategy
- Identify and implement processes designed to protect PHI and prevent HIPAA violations when using healthcare social media
4805
Influenza and Pneumococcal Vaccines in Asthmatic Patients
Session Details
Learning Objectives:
Session Details
Monday, March 3, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Ballroom 6B
1.25 CME/ 1.50 CE
Moderator:
Pedro C. Avila , MD FAAAAI
- Discuss the burden of influenza and invasive pneumococcal disease in asthmatic patients
- Describe the types, benefits and risks of influenza and pneumococcal vaccines for asthmatic patients
4807
Standardization of Oral Food Challenges: How Golden is the Gold Standard?
Session Details
Learning Objectives:
Session Details
Monday, March 3, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Ballroom 6DE
1.25 CME/ 1.50 CE
Moderator:
Scott H. Sicherer , MD FAAAAI
- Highlight the different methodologies for oral food challenges
- Review the controversies around objective stopping criteria and the evidence base for this
- Describe how and when to use different types of challenge methodologies
4808
FDA: Update from the U.S. Food and Drug Administration
Session Details
Learning Objectives:
Session Details
Monday, March 3, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Ballroom 6A
1.25 CME/ 1.50 CE
Moderator:
F. Estelle R. Simons , MD FAAAAI
- Review recent issues of scientific importance at FDA and their regulatory implications
- Identify issues related to the over-the-counter (OTC) marketing of allergy drug products
- Recognize issues in the clinical development of drug products for eosinophilic asthma
4809
Innate Immune Modulators in the Lung
Session Details
Learning Objectives:
Session Details
Monday, March 3, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Room 7AB
1.25 CME/ 1.50 CE
Moderator:
Harald E. Renz , MD
- Recognize the capacity of surfactant phospholipids in suppression of lung inflammation due to aeroallergen, bacterial infection and viral infection
- Describe how surfactant protein-A and D suppress lung inflammation
- Discuss the therapeutic potential of TLR blockade in the treatment of lung diseases
4810
Allergic Inflammation: New Advances in Chemokines and Cell Signaling
Session Details
Learning Objectives:
Session Details
Monday, March 3, 2014: 4:45 PM-6:00 PM
Convention Center, Upper Level, Room 11AB
1.25 CME/ 1.50 CE
Moderator:
David H. Broide , MB ChB FAAAAI
- Discuss how chemokines such as CCL18 are important in allergic inflammation, particularly in atopic dermatitis
- List how cytokines such as eotaxins play an important role in eosinophilic esophagitis
- Describe the role of mast cells in chronic allergic inflammation and how innate mediators and Th2 inflammation exacerbate allergic disease
4812
Utility of FeNO in the Diagnosis and Management of Asthma: Comparison to Other Measures
Session Details
Learning Objectives:
Session Details
Monday, March 3, 2014: 4:45 PM-6:00 PM
Convention Center, Mezzanine Level, Room 14AB
1.25 CME/ 1.50 CE
Moderator:
Harold S. Nelson , MD FAAAAI
- Describe the factors that alter FeNO in asthma
- Review the appropriate uses of FeNO in children
- Discuss the practical implications of implementing FeNO in clinical practice
4813
Stepping Down Asthma Medications: Benefits and Risks
Session Details
Learning Objectives:
Session Details
Monday, March 3, 2014: 4:45 PM-6:00 PM
Convention Center, Mezzanine Level, Room 15AB
1.25 CME/ 1.50 CE
Moderator:
Chitra Dinakar , MD FAAAAI
- Identify asthma patients who may be good candidates for stepping down their asthma medication
- Describe the risks associated with stepping down asthma medication with the best currently available evidence
- Compare and contrast different types of step down strategies
4814
Chronic Rhinosinusitis in Children
Session Details
Learning Objectives:
Session Details
Monday, March 3, 2014: 4:45 PM-6:00 PM
Convention Center, Mezzanine Level, Room 16AB
1.25 CME/ 1.50 CE
Moderator:
Martin Wagenmann , MD FAAAAI
- Discuss the pathophysiology of CRS in children
- List the workup and medical treatment of children with CRS
- Review the surgical approach to CRS in children after failure of medical therapy
Tuesday, March 4, 2014
6:45 AM-8:00 AM
5051
Glycobiology and Glycoimmunology: From Concepts to Clinical Relevance
Session Details
Learning Objectives:
Session Details
Tuesday, March 4, 2014: 6:45 AM-8:00 AM
Convention Center, Upper Level, Room 2
1.25 CME/ 1.50 CE
Moderator:
Nives Zimmermann , MD FAAAAI
- Explain sialic acid biosynthesis and its role in human biology
- Define the role that glycans play in immune recognition and regulation
5053
Impact of Climate Change on Indoor and Outdoor Aeroallergens
Session Details
Learning Objectives:
Session Details
Tuesday, March 4, 2014: 6:45 AM-8:00 AM
Convention Center, Upper Level, Room 5AB
1.25 CME/ 1.50 CE
Moderator:
Estelle Levetin , PhD FAAAAI
- Review two recent reports on the impact of climate change on environmental exposures
- Summarize changes documented to date on indoor and outdoor allergen exposures that have been related to climate change adaptation factors; Discuss future factors that might be directly or indirectly related to climate change and changes in environmental exposures
- Discuss appropriate changes in allergy practice in response to changing environmental exposures
5054
Teaching Allergy and Immunology to Residents and Medical Students: An Achievable Goal for the Clinical Allergist
Session Details
Learning Objectives:
Session Details
Tuesday, March 4, 2014: 6:45 AM-8:00 AM
Convention Center, Upper Level, Room 8
1.25 CME/ 1.50 CE
Moderator:
Mark H. Moss , MD
- Identify the six core competencies of postgraduate medical training
- Describe resources to enhance teaching of trainees in the office setting
- Discuss qualities of a clinical rotation that lend value to a medical training program
3:30 PM-4:45 PM
5804
Challenges and Interventions to Improve Adherence in Urban Minority Populations with Asthma
Session Details
Learning Objectives:
Session Details
Tuesday, March 4, 2014: 3:30 PM-4:45 PM
Convention Center, Upper Level, Room 4
1.25 CME/ 1.50 CE
Moderator:
Cynthia S. Rand , PhD
- Discuss barriers to adherence in urban minority populations with asthma
- Discuss the efficacy of a problem solving intervention to improve adherence in urban adults with asthma
- Evaluate the efficacy of an mp3 player and peer support intervention to improve adherence in urban minority adolescents with asthma
5805
Allergic Inflammation: New Insights into Key Innate Mediators
Session Details
Learning Objectives:
Session Details
Tuesday, March 4, 2014: 3:30 PM-4:45 PM
Convention Center, Upper Level, Room 1AB
1.25 CME/ 1.50 CE
Moderator:
Steve N. Georas , MD
- Explain the importance of type 2 innate lymphoid cells in mediating the initial steps of allergic inflammation
- Review the importance of airway epithelial cells and the effect of stress on production of inflammatory exosomes in allergic airway inflammation
- Recognize the importance of innate type 2 cytokines and their receptors in human asthma
5808
Follicular Helper T Cells in Health and Disease
Session Details
Learning Objectives:
Session Details
Tuesday, March 4, 2014: 3:30 PM-4:45 PM
Convention Center, Mezzanine Level, Room 16AB
1.25 CME/ 1.50 CE
Moderator:
John W. Steinke , PhD FAAAAI
- Discuss how follicular helper T cells develop
- Describe how vaccines can be used to modulate follicular helper T cell function
- Describe the mechanisms through which follicular helper T cells participate in the development of autoimmunity